CLINICAL STUDY OF CLARITHROMYCIN SUSTAINED-RELEASE TABLETS COMBINED WITH BUDESONIDE ATOMIZATION INHALATION IN THE TREATMENT OF CHRONIC PHARYNGITIS

Xilan Gu, Wenbin Wang, Fang Liu, Fei Ye, Xiaodong Yin^*

Department of Otolaryngology (ENT), Suzhou Municipal Hospital, The Affiliated Suzhou Hospital Of Nanjing Medical University, Suzhou 215000, Jiangsu, China

Objective: To analyze the clinical efficacy of clarithromycin sustained-release tablets combined with the budesonide atomization inhalation for chronic pharyngitis. 

Methods: The medical records of 90 patients with chronic pharyngitis admitted to our hospital from January 2020 to January 2022 were retrospectively analyzed. According to the grouping of therapeutic medication in patients, the patients treated with the budesonide atomization inhalation were enrolled in group q. On this basis, the patients treated with the combination of the clarithromycin sustained release tablets were enrolled in group p, with 45 cases in each group. The clinical efficacy of the two groups was compared and analyzed. 

Results: Compared with before treatment, in both groups, the levels of TNF-α and IL-6 were markedly lower (P<0.05), the IL-2 levels were memorably higher (P<0.05), the levels of CD3⁺, CD4⁺ and CD4⁺/CD8⁺ were obviously higher (P<0.05) and the CD8⁺ levels were markedly decreased (P<0.05). Compared with group q, the levels of TNF-α and IL-6 were dramatically lower (P<0.05), the IL-2 level was obviously higher (P<0.05), the levels of CD3⁺, CD4⁺ and CD4⁺/CD8⁺ were visibly higher (P<0.05), the CD8⁺ level was lower (P<0.05), and the obviously effective rate and total effective rate were obviously higher (P<0.05). During the 1-year follow-up visit, 12 patients had recurrence in group q and 2 patients had recurrence in group p, and the recurrence rate was visibly higher compared with group p (P<0.05). Compared with group q, the probability of adverse reactions like nausea and vomiting, and diarrhea and abdominal distension was lower, with no significant difference in the total incidence of adverse reactions in both groups (P>0.05). 

Conclusion: The combination of the budesonide atomization inhalation and the clarithromycin sustained-release tablets can effectively alleviate the inflammatory level of patients with chronic pharyngitis and improve the body immunity, with the low recurrence rate, safety and effectiveness, which has a positive impact on improving the clinical efficacy of chronic pharyngitis.